ClinicalTrials.gg
Status unknownNCT05177939Updated Dec 1, 2022

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

A Phase 3 interventional study of NPB-01 and NPB-01-ME in Autoimmune Encephalitis, sponsored by Nihon Pharmaceutical Co., Ltd. Status unknown at 1 site in Japan. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2022-12-01.

Sponsored by Nihon Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Study summary

To compare the efficacy and safety of NPB-01 in patients with autoimmune encephalitis refractory to steroid pulse therapy using steroid pulse therapy as a control.

02

Conditions studied

  • Autoimmune Encephalitis
03

In context

Autoimmune Diseases of the Nervous System

123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 63 interventional studies indexed under Autoimmune Diseases of the Nervous System.

Browse Autoimmune Diseases of the Nervous System studies →

Lead sponsor

Nihon Pharmaceutical Co., Ltd is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • \< At 1st registration > Patients meeting the possible diagnostic criteria for encephalitis
  • \< At 1st registration > Patients with a CASE score of 5 to 22 during the screening period
  • \< At 1st registration > Patients with autoimmune encephalitis in progress (active and requiring therapeutic intervention)
  • \< At 1st registration > IVIG therapy and pulse therapy are considered necessary by the investigator.
  • \< At 1st registration > Patients aged 15 years or older at the time of
  • \< At 2nd registration > Patients who meet any of the following (1) to (6):

    1. Definite diagnostic criteria for autoimmune limbic encephalitis
    2. MRI evidence of demyelination (probable autoimmune encephalitis)
    3. Probabilistic diagnostic criteria for anti-NMDAR encephalitis
    4. Probabilistic diagnostic criteria for Bickerstaff brainstem encephalitis
    5. Probabilistic diagnostic criteria for Hashimoto's encephalopathy
    6. Diagnostic Criteria for Autoimmune Encephalitis with Negative but Probable Autoantibodies
  • \< At 2nd registration > CASE score of 5 to 22 on Day 8 of the previous treatment period
  • \< At 2nd registration > Patients who have had an inadequate response to steroid pulse therapy

Exclusion criteria

Exclusion Criteria:

  • \< At 1st registration > Patients with strongly suspected infectious encephalitis
  • \< At 1st registration > Patients who received immunoglobulin preparations within 8 weeks prior to
  • \< At 1st registration > Patients who received plasma exchange within 4 weeks prior to informed consent
  • \< At 1st registration > Patients who received (Rituximab, cyclophosphamide, etc.) within 4 weeks prior to informed consent
  • \< At 1st registration > Patients who have had tumor resection associated with encephalitis within 4 weeks prior to informed consent
  • \< At 1st registration > Patients with a history of shock or to the ingredients of NPB-01
  • \< At 1st registration > Patients with known IgA deficiency
  • \< At 1st registration > Patients with renal disorder
  • \< At 1st registration > Patients with a current or previous history of cerebral or cardiovascular disorders (Asymptomatic cerebral infarction and myocardial infarction that occurred more than 5 years ago are not applicable.)
  • \< At 1st registration > Patients at high risk of thromboembolism
  • \< At 1st registration > Patients with haemolytic/blood loss anaemia
  • \< At 1st registration > Immunosuppressed/immunocompromised patients
  • \< At 1st registration > Patients with decreased cardiac function
  • \< At 1st registration > Pregnant, expected (desired or planned) pregnant, or breastfeeding patients
  • \< At 1st registration > Use of prohibited medications or treatment in this study
  • \< At 1st registration > Patients who received product in this study (re-enrollment prohibited)
  • \< At 1st registration > Patients who have received treatment with investigational product other than this study within 4 months prior to informed consent
  • \< At 1st registration > Patients with a history of hypersensitivity to methylprednisolone sodium succinate
  • \< At 1st registration > Patients who have a tumor associated with autoimmune encephalitis and are considered to require resection during the study period.
  • \< At 1st registration > Patients receiving intravenous general anesthetics or sedative hypnotics
  • \< At 1st registration > Patients in coma
  • \< At 1st registration > Ventilated patients
  • \< At 1st registration > Patients who cannot undergo protocol-specified tests/assessments
  • \< At 1st registration > Other patients considered ineligible for the study by the investigator
  • \< At 2nd registration > Positive herpes simplex virus DNA qualitative test in the screening period.
  • \< At 2nd registration > Serum creatinine ≥ 2 times the during the screening period.
  • \< At 2nd registration > Total protein ≥ 9 g/dL during the screening period.
  • \< At 2nd registration > Patients with hematocrit ≥ 55% during the screening period
  • \< At 2nd registration > Patients who meet any of the exclusion criteria at the time of first registration
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    NPB-01

    Intravenous immunoglobulin

    Drug: NPB-01

  • Active comparator
    NPB-01-ME

    methylprednisolone sodium succinate

    Drug: NPB-01-ME

Interventions

  • DrugNPB-01

    NPB-01 will be administered for the treatment of autoimmune encephalitis

    Also known as: Intravenous immunoglobulin

  • NPB-01-ME will be administered for the treatment of autoimmune encephalitis

    Also known as: methylprednisolone sodium succinate

06

What researchers measure

Primary outcomes

  1. Proportion of responders in CASE (Clinical Assessment Scale in Autoimmune Encephalitis)

    A responder is defined as a patient whose CASE score at Week 4 of the post-treatment follow-up period after treatment with investigational product improved by 40% or more compared to the pre-treatment period.

    Time frame: 4 weeks

Secondary outcomes

  1. CASE

    The change in CASE score at each time point after the start of treatment with investigational product compared with that on Day 8 of the pretreatment period will be compared between the arms. Changes in CASE scores divided into three segments (0 -4: excellent, 5 -9: moderate, 10 -27: poor) will also be compared. In addition, the period until CASE score becomes 4 points or less after the start of treatment with investigational product will be checked.

    Time frame: 1, 2, 3, 4, 6, 8, 12 weeks

  2. mRS

    Changes in mRS at each time point after the start of investigational product treatment compared with Day 8 of the pretreatment period will be compared between the arms.

    Time frame: 1, 2, 3, 4, 6, 8, 12 weeks

  3. GCS

    To compare the change in GCS at each time point after the start of investigational product with that on Day 8 of the pretreatment period between the arms.

    Time frame: 1, 2, 3, 4, 6, 8, 12 weeks

  4. MMSE-J

    The change in MMSE-J at each time point after the start of investigational product as compared with Day 8 of the pretreatment period will be compared between the arms.

    Time frame: 4, 8, 12 weeks

  5. FAB

    The change in FAB at each time point after the start of investigational product as compared with Day 8 of the pretreatment period will be compared between the arms.

    Time frame: 4, 8, 12 weeks

  6. Disappearance of abnormal EEG findings

    The proportion of subjects in whom abnormal findings in EEG disappeared at each time point after the start of investigational product as compared with Day 8 of the pretreatment period will be compared between the arms.

    Time frame: 4, 12 weeks

  7. Disappearance of abnormal head MRI findings

    The proportion of subjects in whom abnormal findings in head MRI disappeared at each time point after the start of investigational product as compared with Day 8 of the pretreatment period will be compared between the arms.

    Time frame: 4, 12 weeks

  8. Cerebrospinal fluid test

    The proportion of subjects in whom the cell count returned to within the reference range (≤ 5/μl) and the proportion of subjects in whom the protein count returned to within the reference range (15.0 \~ 45.0 mg/dL) at each time point after the start of investigational product treatment as compared with Day 8 of the pretreatment period will be checked.

    Time frame: 4, 12 weeks

  9. Duration of hospitalization

    Duration of hospitalization after the start of treatment with investigational product to be compared between the arms.

    Time frame: 12 weeks

  10. mRS proportion

    The proportions of subjects with an mRS score of ≤ 2, subjects with an improvement of ≥ 1 point, and subjects with an improvement of ≥ 2 points will also be compared. Also, the time to mRS improvement after the start of treatment with investigational product (≤ 2 points, ≥ 1 point improvement, ≥ 2 points improvement) .

    Time frame: 1, 2, 3, 4, 6, 8, 12 weeks

  11. GCS proportion

    Changes in GCS when divided into three segments (15-13: Mild, 12-9: Moderate, 8-3: Severe) will also be compared. In addition, the period until the GCS score reaches 13 or higher after the start of treatment with investigational product will be checked.

    Time frame: 1, 2, 3, 4, 6, 8, 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Trial site 1
    Ube, Yamaguchi, Japan
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for May 2024, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2021
First posted
Jan 5, 2022
StartActual
Mar 3, 2022
Primary completionEst.
May 31, 2024
CompletionEst.
Oct 31, 2024
Last update
Dec 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05177939
Lead sponsor
Nihon Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Jan 5, 2022
Start date
Mar 3, 2022
Primary completion
May 31, 2024 (estimated)
Completion
Oct 31, 2024 (estimated)
Last update
Dec 1, 2022

Study contacts

Mamoru Ota
Contact
kaihatsu@nihon-pharm.co.jp
03-5148-7574
Mamoru Ota
study chair · Nihon Pharmaceutical Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion